Advertisement
Letter to the Editor| Volume 75, ISSUE 4, P1002, October 2021

Reply to: “TIPS and liver transplantation should always be discussed together”

  • Dominik Bettinger
    Correspondence
    Corresponding author. Address: Medical Center University of Freiburg, Department of Medicine II, Hugstetter Str. 55, D- 79106 Freiburg, Germany; Tel.: +49 761/270-34010.
    Affiliations
    Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany

    Berta-Ottenstein Programme, Faculty of Medicine, University of Freiburg, Germany
    Search for articles by this author
  • Robert Thimme
    Affiliations
    Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany
    Search for articles by this author
  • Michael Schultheiss
    Affiliations
    Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany
    Search for articles by this author

      Linked Article

      • Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival
        Journal of HepatologyVol. 74Issue 6
        • Preview
          Transjugular intrahepatic portosystemic shunt (TIPS) implantation is an effective and safe treatment for complications of portal hypertension. Survival prediction is important in these patients as they constitute a high-risk population. Therefore, the aim of our study was to develop an alternative prognostic model for accurate survival prediction after planned TIPS implantation.
        • Full-Text
        • PDF
      • TIPS and liver transplantation should always be discussed together
        Journal of HepatologyVol. 75Issue 4
        • Preview
          We read with interest the study by Bettinger et al.,1 proposing a new prognostic model of survival after transjugular intrahepatic portosystemic shunt (TIPS) placement, called the Freiburg index of post-TIPS survival (FIPS). In a large cohort of 1,871 patients with cirrhosis who were candidates for elective TIPS placement (i.e. for refractory ascites or secondary prophylaxis of variceal bleeding), the authors reported that age, bilirubin, albumin and creatinine were factors strongly associated with post TIPS survival.
        • Full-Text
        • PDF
      To the Editor:
      With great interest, we read the letter by Rudler et al. focusing on the Freiburg index of post-TIPS survival (FIPS) score in the setting of liver transplantation (LT).
      • Rudler M.
      • Savier E.
      • Alioua I.
      • Sultanik P.
      • Thabut D.
      TIPS and liver transplantation should always be discussed together.
      ,
      • Bettinger D.
      • Sturm L.
      • Pfaff L.
      • Hahn F.
      • Kloeckner R.
      • Volkwein L.
      • et al.
      Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.
      This example of a multidisciplinary TIPS/LT board is an important step towards personalized treatment of patients with advanced cirrhosis and may serve as a model for other centers. The authors also analyzed the application of the FIPS score in this approach and they were able to show that the FIPS score adequately selects patients who need LT.
      Rudler et al. mention that only a minority of patients (1.5%) received LT in our cohort.
      • Bettinger D.
      • Sturm L.
      • Pfaff L.
      • Hahn F.
      • Kloeckner R.
      • Volkwein L.
      • et al.
      Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.
      This might be explained by 2 facts: A) There is a lack of donor organs within the Eurotransplant region, leading to a much smaller number of patients allocated to LT in our cohort compared to the French cohort from Paris. B) The model for end-stage liver disease (MELD) score, used for LT allocation, does not sufficiently consider disease progression for patients with hepatocellular carcinoma, primary sclerosing cholangitis or other rare diseases. Therefore, these patients receive exceptional MELD (exMELD) points, increasing their chance of LT. In contrast, waiting list mortality is high in patients with advanced cirrhosis without exMELD.
      Interestingly, the FIPS score sufficiently identifies patients who do not benefit from TIPS implantation but should be allocated to LT early. To date, it is unclear if the FIPS score may also predict mortality on the waiting list and therefore may be useful in this setting. Moreover, it has to be analyzed if an increase of the FIPS score on the waiting list is associated with earlier allocation to LT. These open questions are highly relevant to conclusively clarify the role of the FIPS score in the context of LT. Further studies will have to analyze the association between FIPS risk groups and waiting list mortality and compare their predictive discrimination to the MELD score.
      In summary, as shown by several independent groups, the FIPS score is a reliable tool for identifying high risk patients with decompensated cirrhosis.
      • Kraglund F.
      • Gantzel R.H.
      • Jepsen P.
      • Aagaard N.K.
      External validation of the freiburg index of post-TIPS survival.
      • Wang Q.
      • Bai W.
      • Han G.
      Freiburg index of post-TIPS survival: the first score for individual prediction and a complementary tool for risk stratification.
      • Stockhoff L.
      • Schneider H.
      • Tergast T.L.
      • Cornberg M.
      • Maasoumy B.
      Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?.
      Further, it will be important to analyze if the FIPS score could be useful in decision-making, not only in the TIPS setting, but also in patients allocated for LT.

      Financial support

      DB is supported by the Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg.

      Authors’ contributions

      Drafting the manuscript: DB, MS
      Revision for important intellectual content: MS, RT

      Conflict of interest

      DB: Consultant: Bayer Healthcare, Boston Scientific, Shionogi. Lectures: Falk Foundation. MS: Consultant: Bayer Healthcare, L.W.Gore Lectures: Falk Foundation.
      Please refer to the accompanying ICMJE disclosure forms for further details.

      Supplementary data

      The following is the supplementary data to this article:

      References

        • Rudler M.
        • Savier E.
        • Alioua I.
        • Sultanik P.
        • Thabut D.
        TIPS and liver transplantation should always be discussed together.
        J Hepatol. 2021; 75: 1000-1001
        • Bettinger D.
        • Sturm L.
        • Pfaff L.
        • Hahn F.
        • Kloeckner R.
        • Volkwein L.
        • et al.
        Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.
        J Hepatol. 2021; 74: 1362-1372
        • Kraglund F.
        • Gantzel R.H.
        • Jepsen P.
        • Aagaard N.K.
        External validation of the freiburg index of post-TIPS survival.
        J Hepatol. 2021; 75: 746-747
        • Wang Q.
        • Bai W.
        • Han G.
        Freiburg index of post-TIPS survival: the first score for individual prediction and a complementary tool for risk stratification.
        J Hepatol. 2021; 75: 747-749
        • Stockhoff L.
        • Schneider H.
        • Tergast T.L.
        • Cornberg M.
        • Maasoumy B.
        Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?.
        J Hepatol. 2021; 75: 487-489